Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
3
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Syndrome of Inappropriate Antidiuretic Hormone Secretion
View Full LandscapeTarget Indication
Syndrome of Inappropriate Antidiuretic Hormone Secretion
Clinical Trial
NCT03048747Last updated: 12/17/2025
No patent data available. Pre-approval drugs may not have Orange Book listings.
Tolvaptan Accord
Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
View on EMAJinarc
Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.
View on EMASamsca
Treatment of adult patients with hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion (SIADH).
View on EMA